Novo Nordisk A/S (NVO) Stock Analysis & DCF Valuation

Novo Nordisk A/S logo

NVO · NYSE ·

Buy

High confidence

Danish multinational pharmaceutical company, leading the GLP-1 weight loss market with Ozempic and Wegovy. Faces massive demand and supply constraints.

Novo Nordisk A/S Intrinsic Value & DCF Valuation

Our discounted cash flow (DCF) model estimates Novo Nordisk A/S fair value at $NaN per share, compared to the current market price of $NaN. This implies +67.3% upside from today's price.

Fair Value (DCF) $NaN
Current Market Price $NaN
Upside / Downside +67.3%

NVO Key Financial Metrics

Market Cap $591.2 Billion
P/E Ratio 52.63
Dividend Yield 0.35%
Analyst Target Price $168.75

Novo Nordisk A/S Long-Term Stock Outlook

Novo Nordisk is poised for significant continued growth as long as they can scale production and fend off immediate competition in the metabolic disorder space. Market penetration potential is enormous.

Bullish Factors

  • [object Object]
  • [object Object]
  • [object Object]

Key Risks

  • [object Object]
  • [object Object]
  • [object Object]

NVO Analyst Sentiment & Market Consensus

Analysts maintain a strong 'Buy' consensus, though caution exists regarding valuation and immediate supply bottlenecks. The general tone is highly optimistic about long-term market capture.

Should You Buy NVO Stock?

Recommendation: Buy High confidence

No recommendation provided

Frequently Asked Questions

Is NVO a good stock to buy?

Based on our AI analysis, Novo Nordisk A/S (NVO) is rated as Buy with high confidence. Danish multinational pharmaceutical company, leading the GLP-1 weight loss market with Ozempic and Wegovy. Faces massive demand and supply constraints.

What is NVO stock price target?

Our DCF valuation model estimates Novo Nordisk A/S (NVO) fair value at $NaN, suggesting +67.3% downside potential from current price of $NaN.

What is NVO fair value?

The fair value for Novo Nordisk A/S (NVO) is estimated at $NaN based on discounted cash flow (DCF) analysis. This represents +67.3% downside from the current price.

*This analysis is for informational purposes only and should not be taken as financial advice.*

© 2025 stockpickr - AI-Powered Stock Analysis

View more stock analyses